Biotechnology - Anti-virals, USA

Filter

Current filters:

Anti-viralsUSA

Popular Filters

1 to 25 of 32 results

US declaration under PREP Act to support Ebola vaccines development

10-12-2014

US Health and Human Services Secretary Sylvia Burwell yesterday announced a declaration under the Public…

Anti-viralsBavarian NordicBiotechnologyGlaxoSmithKlineJanssenJohnson & JohnsonLegalNewLink GeneticsResearchTropical diseasesUSAVaccines

Government action needed to slash prices for hepatitis C treatments, says US advocacy

Government action needed to slash prices for hepatitis C treatments, says US advocacy

04-12-2014

The US federal government should act to dramatically lower the cost of new and prohibitively pricey medications…

Anti-viralsBiotechnologyGilead SciencesPricingSovaldiUSA

Advantages of Gilead’s Harvoni over emerging hepatitis C treatments

Advantages of Gilead’s Harvoni over emerging hepatitis C treatments

10-11-2014

US surveyed specialists anticipate prescribing Gilead Sciences’ Harvoni to a high proportion of their…

Anti-viralsBiotechnologyGilead SciencesHarvoniJanssenMarkets & MarketingMedivirOlysioSovaldiUSA

Janssen’s Olysio/sofosbuvir combination cleared by FDA

Janssen’s Olysio/sofosbuvir combination cleared by FDA

06-11-2014

The Food and Drug Administration has approved US health care giant Johnson & Johnson's Olysio (simeprevir)…

Anti-viralsBiotechnologyJohnson & JohnsonMedivirOlysioRegulationsofosbuvirUSA

Department of Defense contracts Profectus to develop its VesiculoVax Zaire-Ebola virus vaccine

Department of Defense contracts Profectus to develop its VesiculoVax Zaire-Ebola virus vaccine

31-10-2014

The US Department of Defense has contracted the manufacture and IND-enabling preclinical testing of the…

Anti-viralsBiotechnologyProfectus BioSciencesResearchUSAVesiculoVax Zaire-Ebola

Gilead third-qtr sales beat expectations, but Sovaldi disappoints

Gilead third-qtr sales beat expectations, but Sovaldi disappoints

29-10-2014

There was mixed news late yesterday from US anti-virals major Gilead Sciences, when the biotech posted…

Anti-viralsBiotechnologyFinancialGilead SciencesHarvoniSovaldiUSA

Harvoni will keep Gilead atop hepatitis C treatment landscape, says analyst

Harvoni will keep Gilead atop hepatitis C treatment landscape, says analyst

23-10-2014

The recent US Food and Drug Administration approval of Harvoni (ledipasvir/sofosbuvir), Gilead Sciences’…

Anti-viralsBiotechnologyGilead SciencesHarvoniMarkets & MarketingPricingSovaldiUSA

Profectus BioSciences gets US government funding for Ebola vaccine development

17-10-2014

Under a one-year contract with US biotech firm Profectus BioSciences, the US Department of Health and…

Anti-viralsBiotechnologyFinancialProfectus BioSciencesResearchUSA

FDA approves Gilead’s Harvoni, the first combo pill for hepatitis C

FDA approves Gilead’s Harvoni, the first combo pill for hepatitis C

12-10-2014

As was largely expected, the US Food and Drug Administration on Friday approved biotech firm Gilead Sciences’…

Anti-viralsBiotechnologyGilead SciencesHarvoniPricingRegulationSovaldiUSA

Chimerix reports preliminary data showing antiviral brincidofovir improves survival in adenovirus

Chimerix reports preliminary data showing antiviral brincidofovir improves survival in adenovirus

09-10-2014

Antiviral biopharma company Chimerix has reported preliminary data indicating that its investigational…

Anti-viralsBiotechnologybrincidofovirChimerixResearchUSA

Gilead's TAF-based HIV regimen meets 48-week primary objective

Gilead's TAF-based HIV regimen meets 48-week primary objective

24-09-2014

Gilead Sciences says that two Phase III clinical trials (Studies 104 and 111) evaluating an investigational…

Anti-viralsBiotechnologyGilead SciencesResearchtenofovir alafenamideUSA

SIGA Technologies files for Chapter 11 reorganization

SIGA Technologies files for Chapter 11 reorganization

16-09-2014

Biological warfare defense firm SIGA Technologies has filed a voluntary petition for relief under chapter…

Anti-viralsBiotechnologyFinancialLegalPharmAtheneSIGA TechnologiesTecovirimatUSA

Gilead's monopoly in HIV therapies to be toppled by Viiv's Triumeq; report

Gilead's monopoly in HIV therapies to be toppled by Viiv's Triumeq; report

09-09-2014

The recent US Food and Drug Administration and European Commission approval of HIV specialist ViiV Healthcare’s…

Anti-viralsAtriplaBiotechnologyGilead SciencesGlobalDataHIVMarkets & MarketingStribildTriumeqUSAViiV Healthcare

US HHS contracts with Mapp Biopharmaceutical to develop Ebola drug

03-09-2014

The US Department of Health and Human Services has awarded a $25 million contract to Mapp Biopharmaceutical…

Anti-viralsBiotechnologyFinancialMapp BiopharmaceuticalResearchTropical diseasesUSAZMapp

Gilead gets favorable ruling in Roche arbitration

Gilead gets favorable ruling in Roche arbitration

17-08-2014

US biotech major Gilead Sciences said on Friday in a Security and Exchange Commission filing that an…

Anti-viralsArbitrationBiotechnologyBusiness FinanceBusiness FinanceGilead SciencesLegalPatentsPharmassetRocheSovaldiUSA

Vertex to drop hep C drug Incivek following poor sales

14-08-2014

Struggling US Biotech firm Vertex Pharmaceuticals has said it will cease marketing its hepatitis C treatment…

Anti-viralsBiotechnologyGilead SciencesHepatitis C treatmentIncivekJohnson & JohnsonMarkets & MarketingSovaldiTelaprevirUSAVertex Pharmaceuticals

Sanofi and PATH the first to bring large quantities of semisynthetic artemisinin antimalarial treatment to market

Sanofi and PATH the first to bring large quantities of semisynthetic artemisinin antimalarial treatment to market

12-08-2014

French drug major Sanofi and Seattle-based PATH have become the first to deliver large-scale batches…

Anti-viralsartemisininBiotechnologyMarkets & MarketingPATHSanofiUSA

Tekmira Pharma in focus as the world awaits Ebola treatment

Tekmira Pharma in focus as the world awaits Ebola treatment

06-08-2014

The outbreak of the deadly and highly infectious Ebola disease in Africa has already claimed many hundreds…

Anti-viralsBCX4430BioCryst PharmaceuticalsBiotechnologyEbolaMapp BiopharmaceuticalResearchRest of the WorldTekmira PharmaceuticalsTKM-EbolaUSA

Theraclone out-licenses HIV bNAbs to Gilead

Theraclone out-licenses HIV bNAbs to Gilead

01-08-2014

US privately-held drug developer Theraclone Sciences has entered into an agreement with biotech major…

Anti-viralsBiotechnologyBusiness FinanceGilead SciencesHIV/AIDSLicensingTheraclone SciencesUSA

Hepatitis C cured in co-infected HIV patients

Hepatitis C cured in co-infected HIV patients

21-07-2014

A multicenter team of researchers report that in a Phase III clinical trial, a combination drug therapy…

Anti-viralsAntiviralsBiotechnologyGilead SciencesHepatitis CResearchRibavirinsofosbuvirSovaldiThe Johns Hopkins University School of MedicineUSA

The price of NOT curing hepatitis C - by Robert Zirkelbach

The price of NOT curing hepatitis C - by Robert Zirkelbach

20-07-2014

Over the past few months, there has been increased focus on the price of a new cure for hepatitis C,…

Anti-viralsBiotechnologyFinancialHealthcareHepatitis CHepatitis CLiver transplantsMedicineTradeUSA

US Senators press for details on Gilead’s Sovaldi pricing

US Senators press for details on Gilead’s Sovaldi pricing

12-07-2014

Adding to previous criticism from the likes of the medical humanitarian organization Medecins Sans Frontieres…

Anti-viralsBiotechnologyGilead SciencesPoliticsPricingSovaldiUSA

1 to 25 of 32 results

COMPANY SPOTLIGHT

Parexel

Parexel

Back to top